A Phase 3 interventional study of Ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, sponsored by Hoffmann-La Roche. Terminated at 193 sites in 29 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-01-15.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting — 2 open to participants now, 5 under way, 3 of them phase 3. ocrelizumab · Multiple Sclerosis, Relapsing-Remitting.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, this one has the largest enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 4th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting are open now, in 2 countries. Recruiting first, the newest first:
Celltrion · Sites in Poland
Ages 18–55
University of California, San Francisco · Sites in United States
Ages 18–65
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2017.
This study's enrollment of 1,225 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 404 across the 10 interventional studies. Of the 5 that completed or were terminated, 5 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche: 2 open now, 5 under way, 2 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2017, is one of 6 in phase 3, and was the 8th registered.
Hoffmann-La Roche’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2004.
3 of the studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05906992Phase 3CelltrionA Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | 2027-02 |
| NCT05296161Amsterdam UMC, location VUmcB Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis | 2027-02 |
| NCT06495593University of California, San FranciscoEffects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 14 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.
The optional shorter infusion substudy will evaluate the safety of a shorter infusion of ocrelizumab in a subgroup of participants with early stage RRMS enrolled in the main MA30143 study. Approximately 700 patients will be enrolled in the substudy, and will receive additional 600 mg ocrelizumab administered in a shorter time frame.
Inclusion Criteria:
Exclusion Criteria:
Exclusions Related to General Health:
Exclusions Related to Medications:
Exclusion related to Shorter Infusion Substudy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ocrelizumab will be administered intravenously (IV) as two 300-milligram (mg) infusions (infusion length=2.5 hours) on Days 1 and 15, followed by one 600-mg infusion dose every 24 weeks (+/- 14 days) for a maximum of 8 doses throughout the 192 weeks treatment period.
Drug: Ocrelizumab
At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 3.5 hours every 24 weeks for the remainder of the study duration
Drug: Ocrelizumab
At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 2 hours followed by sodium chloride given as a slow infusion over the remaining 1.5 hours to mimic the standard-length infusion (3.5 hour) every 24 weeks for the remainder of the study duration
Drug: Ocrelizumab
Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks and 48 Weeks as Measured Using Expanded Disability Status Scale (EDSS)
The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits for a minimum of 24 weeks/48 weeks.
Time frame: Baseline up to 4 years
Percentage of Participants With 24-Week and 48-Week Confirmed Disability Improvement (CDI) During the Year 1 Treatment Period, as Measured Using EDSS
CDI is defined as an improvement of ≥1 point on the EDSS score confirmed at a regular scheduled visit at least 24/48 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).
Time frame: At Weeks 24 and 48 during Year 1
Percentage of Participants Event-Free for CDP Sustained for at Least 24 and 48 Weeks at Year 1, as Measured Using EDSS
The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.
Time frame: Year 1 (Weeks 24 and 48)
Percentage of Participants With 24-Week and 48-Week CDI During the Year 2 Treatment Period, as Measured Using EDSS
CDI is defined as an improvement of 1 point on the EDSS score confirmed at a regular scheduled visit at least 24/48 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).
Time frame: At Weeks 48, 72 and 96 during Year 2
Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 2, as Measured Using EDSS
The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.
Time frame: Year 2 (Weeks 72 and 96)
Percentage of Participants With 24-Week and 48-Week CDI at Year 4, as Measured Using EDSS
CDI is defined as an improvement of 1 point on the EDSS score confirmed at a regular scheduled visit at least 24 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).
Time frame: At Weeks 144, 168 and 192 during Year 4
Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 4, as Measured Using EDSS
The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.
Time frame: Year 4 (Weeks 168 and 192)
Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 1, As Measured Using EDSS
Time frame: Year 1 (Week 48)
Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 2, As Measured Using EDSS
Time frame: Year 2 (Week 96)
Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 3, As Measured Using EDSS
Time frame: Year 3
Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 4, As Measured Using EDSS
Time frame: Year 4
Mean Change From Baseline in EDSS Score at Week 24
Time frame: From Baseline to Week 24
Mean Change From Baseline in EDSS Score at Week 48
Time frame: From Baseline to Week 48
Mean Change From Baseline in EDSS Score at Week 72
Time frame: From Baseline to Week 72
Mean Change From Baseline in EDSS Score at Week 96
Time frame: Baseline, Week 96
Mean Change From Baseline in EDSS Score at Week 120
Time frame: Baseline, Week 120
Mean Change From Baseline in EDSS Score at Week 144
Time frame: Baseline, Week 144
Mean Change From Baseline in EDSS Score at Week 168
Time frame: Baseline, Week 168
Mean Change From Baseline in EDSS Score at Week 192
Time frame: Baseline, Week 192
Percentage of Participants Without Protocol-Defined Event of Disease Activity
Protocol-defined event of disease activity is defined as having at least one of the following: (1). protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis \[MS\], as determined using EDSS/Functional Systems Score \[FSS\] assessment). (2). CDP, as determined using EDSS. (3). a T1 Gd-enhanced lesion after Week 8 (4). a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI) after Week 8 compared to the Week 8 MRI scan.
Time frame: Baseline up to 4 years
Percentage of Participants Without Relapse
Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.
Time frame: Baseline up to 4 years
Annualized Relapse Rate
Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment. The adjusted annualized relapse rate is reported which is: Adjusted by age at disease diagnosis, Baseline EDSS, Presence of T1 Gd-enhanced lesion at screening and Presence of relapses in the last year prior to enrollment. Log-transformed exposure time is included as an offset variable. The report contains data up to week 192 of the treatment period of each individual participant.
Time frame: Baseline up to 4 years
Sub Study: Number of Participants With IRRs Occurring During or Within 24 Hours Following the First Infusion After Randomization to the Shorter Infusion Substudy
Time frame: Week 24 through Week 144
Percentage of Participants Who Are Relapse Free
Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.
Time frame: Week 192
Percentage of Participants With No Evidence of Protocol Defined Disease Activity
Protocol-defined disease activity is defined as having at least one of the following: (1). protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis \[MS\], as determined using EDSS/Functional Systems Score \[FSS\] assessment). (2). CDP, as determined using EDSS. (3). a T1 Gd-enhanced lesion after Week 8. (4). a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI) after Week 8 compared to the Week 8 MRI scan. Event-free rate
Time frame: Weeks 96, 144, 192
Percentage of Participants Without Protocol-defined Event of Evidence of Progression (NEP)
NEP is defined as no progression sustained for at least 24 weeks on all of the following three components (CDP; 20 percent \[%\] increase from baseline in timed 25 Foot Walk Test \[T25FWT\]; 20% increase from baseline in timed 9 hole peg test \[9HPT\]). CDP will be assessed using EDSS.
Time frame: Weeks 96, 192
Percentage of Participants With no Evidence of Progression Sustained for At Least 24 Weeks and no Active Disease (NEPAD)
NEPAD is defined as no progression on all of the three components of NEP (CDP, T25FWT, 9HPT), no new relapse and no enlarging or new T2 or T1 Gd-enhancing lesion. CDP will be assessed using EDSS. Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.
Time frame: Weeks 96, 192
Secondary: Change From Baseline in Multiple Sclerosis Functional Composite Score (MSFC) Total
MSFC combines the following: Timed 25 Foot Walk Test \[T25FWT\] for leg function \&ambulation measured in seconds (sec). The longer it takes to walk, higher the score indicating deterioration; 9 Hole Peg Test \[9HPT\] for arm \& handf unction measured in sec. Higher score=more time taken to complete test indicating deterioration. Paced Auditory Serial Addition Test \[PASAT\] for cognitive function (score range: 0-60, higher score=better cognitive processing speed). MSFC composite={\[Average(1/9-HPT)-Baseline Mean(1/9-HPT)/Baseline Std Dev(1/9-HPT)\]+\[-(Average T25FWT-Baseline Mean T25FWT)/Baseline Std-Dev T25FWT\]+\[(PASAT-3-BaselineMean PASAT-3)/Baseline Std Dev PASAT-3\]}/ 3.0. MSFC is based on the concept that scores for these 3 dimensions are combined to create a single score to detect change over time in a group of MS patients. Higher composite score=better overall function. Lower score=worse overall function. Higher mean change in total MSFC score=functional improvement at cohort level.
Time frame: Weeks 24, 48, 72, 96, 120, 144, 168, 192
Change From Baseline in MSFC Composite Timed 25 Foot Walk Test (T25FW) Score.
The change in the mean score of T25FW is reported below. The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, the higher score, which indicates deterioration. Lower times indicate better performance and greater mobility. Higher times indicate worse performance and greater impairment. Subsequently, the lower the mean change in the score over time, the better performance.
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192
Change From Baseline in MSFC Composite 9 Hole Peg Test (9HPT) Score
The mean change in 9 Hole Peg Test (9HPT)-score is reported. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. The number of seconds it takes to complete the test, the higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.
Time frame: Weeks 24, 48, 72, 96, 120, 144, 168, 192
Change From Baseline in MSFC Composite (Paced Auditory Serial Addition Test [PASAT]) Score
Mean change in the Paced Auditory Serial Addition Test \[PASAT\] score is reported. PASAT measures cognitive function. A total of 60 single digit numbers are presented by an audiotape/CD-rom at a constant rate in every 3 seconds (PASAT-3). Participants are required to add each new number to the one immediately before it. Due to the relative complexity of this test, a practice trial with a set of 10 numbers should be performed before the original test. Participants are allowed up to 3 practice trials. Two sets of numbers (forms A \& B) are developed to be used alternatively in every visit to minimize memorizing. The number of correct answers is recorded. The PASAT score ranges from 0 to 60, with higher values representing a better outcome in cognitive processing speed. Subsequently, higher values in mean changes from baseline over the study time indicate improvement in cognitive function.
Time frame: Weeks 24, 48, 72, 96, 120, 144, 168, 192
Change From Baseline in Cognitive Performance as Measured by Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) - Symbol Digits Modalities Test (SDMT)
BICAMS is assessing cognitive processing speed and verbal and visual memory. SDMT assesses processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 second time span. The higher the results, the better processing speed/working memory.
Time frame: Baseline, Weeks 48, 96, 144, 192
Change From Baseline in Cognitive Performance as Measured by BICAMS -California Verbal Learning Test-II (CVLT-II)
BICAMS assesses cognitive processing speed and verbal and visual memory. The CLVT-II is an assessment of verbal learning and memory which measures recall and recognition scores, encoding strategies, learning rates and error types. A list learning task with 16 words from 4 semantic categories are read over a series of 5 list presentations. Recall is assessed after learning and at a 20-minute delay. The maximum possible score is 80 and a minimum is 0. A higher score indicated better recall.
Time frame: Baseline, Weeks 48, 96, 144, 192
Change From Baseline in Cognitive Performance as Measured by BICAMS - Brief Visuospatial Memory Test-Revised (BVMT-R)
BICAMS assesses cognitive processing speed and verbal and visual memory. BVMT-R assesses visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.
Time frame: Baseline, Weeks 48, 96, 144, 192
Total Number of T1 Gd-Enhancing Lesions as Detected by Brain MRI
Number of Lesions are categorized as followed: 1, 2, 3, \>1, \>3
Time frame: Weeks 24, 48, 96, 144, 192
Total Number of New and/or Enlarging T2 Lesion as Detected by Brain MRI
Number of Lesions are categorized as followed: 1, 2, 3, \>1
Time frame: Baseline, Weeks 24, 48, 96, 144, 192
Change From Baseline in Total T1 Hypointense Lesion Volume as Detected by Brain MRI
Time frame: Baseline, Weeks 48, 96, 144, 192
Total Number of Fluid-Attenuated Inversion-Recovery (FLAIR) Lesion as Detected by Brain MRI
Fluid-Attenuated Inversion-Recovery (FLAIR) Lesion as Detected by Brain MRI was measured for its volumes.
Time frame: Baseline, Weeks 8, 24, 48, 96, 144, 192
Change From Baseline in Brain Volume as Detected by Brain MRI
Percentage change from Normalized brain volume in cm3 (cubic centimeter)values are reported
Time frame: From Baseline to Weeks 24, 48, 96, 144, 192
Percentage of Participants Without Treatment Discontinuation
Time frame: Baseline up to 4 years
Employment Status: Work Productivity and Activity Impairment Questionnaire (WAPI) Score
WPAI scale measures impact of health problems on work productivity and regular activities: Absenteeism (Work Time Missed) measuring % of work time missed due to health issues; Presenteeism:Calculated as the percentage of impairment while working due to health problems. Overall Work Impairment:Calculated by combining absenteeism and presenteeism using the formula:Overall Work Impairment=Absenteeism+(1-Absenteeism)×Presenteeism Overall Work Impairment=Absenteeism+(1-Absenteeism)×Presenteeism This formula accounts for both the time missed and the reduced productivity while at work. Activity Impairment: Calculated as the percentage of impairment in regular activities outside of work. Range: Each component is scored as 0%-100%). Higher % indicate greater impairment and worse outcomes.
Time frame: Baseline, Weeks 24, 48, 96, 120, 144, 192
SymptoMScreen Composite Score
The SMSS consists of 12 items which are assessed on a seven-point Likert scale that ranges from 0 (not at all affected) to 6 (total limitation) \[7\]. The total score ranges from 0 to 72, with higher scores indicating more severe symptom endorsement.
Time frame: Baseline, Weeks 24, 48, 96, 144, 192
Quality of Life: Multiple Sclerosis Impact Scale (MSIS)-29 Questionnaire Score
The 29-item Multiple Sclerosis Impact Scale (MSIS-29) is a questionnaire to examine the impact of multiple sclerosis (MS) on physical and psychological functioning from a patient's perspective, which includes 29 items self-reported measures associated with a physical scale and 9 items with a psychological scale. MSIS-29 scales are generated by summing items and it's ranging from 29-145'. The higher total MSIS-29 scores indicate a greater degree of disability. The mean change in MSIS-29 scores from baseline is reported. The decreasing values in the mean change from baseline indicate functional improvement from patients' perspective
Time frame: Baseline, Weeks 24, 48, 96, 144, 192
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to 4 years
Substudy: Number of Participants With IRR Overall and by Dose at Randomization
Time frame: From Week 24 to Week 144
Substudy: Severity of IRRs
The number of participants with IRRs by most extreme intensity were reported (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 =life-threatening, grade 5 = fatal). Multiple IRRs in one participant are counted only once at the most extreme (highest) intensity observed.
Time frame: From Week 24 to Week 144
Substudy: Number of IRR Symptoms
Time frame: From Week 24 to Week 144
Substudy: IRRs Leading to Treatment Discontinuation
Time frame: From Week 24 to Week 144
A prospective, multicenter, open-label, single-arm effectiveness and safety study enrolled 1225 eligible treatment-naive patients with early stage RMSR. The study consisted of screening period up 4 weeks and open-label treatment with ocrelizumab period up to 192 week.
| Milestone | Main Study - Ocrelizumab | Substudy - Conventional Infusion | Substudy - Shorter Infusion |
|---|---|---|---|
| Started | 1225 | 0 | 0 |
| Completed | 1010 | 0 | 0 |
| Not completed | 215 | 0 | 0 |
| Withdrew: Withdrawal by subject | 77 | 0 | 0 |
| Withdrew: Terminated by sponsor | 14 | 0 | 0 |
| Withdrew: Protocol violation | 15 | 0 | 0 |
| Withdrew: Physician decision | 13 | 0 | 0 |
| Withdrew: Lost to follow-up | 17 | 0 | 0 |
| Withdrew: Adverse event | 25 | 0 | 0 |
| Withdrew: Pregnancy | 7 | 0 | 0 |
| Withdrew: Changed to commercial ocrelizumab | 4 | 0 | 0 |
| Withdrew: Lack of efficacy | 10 | 0 | 0 |
| Withdrew: Death | 12 | 0 | 0 |
| Withdrew: Disease progression | 1 | 0 | 0 |
| Withdrew: Site closure | 3 | 0 | 0 |
| Withdrew: Planned pregnancy | 17 | 0 | 0 |
| Milestone | Main Study - Ocrelizumab | Substudy - Conventional Infusion | Substudy - Shorter Infusion |
|---|---|---|---|
| Started | 0 | 373 | 372 |
| Completed | 0 | 0 | 2 |
| Not completed | 0 | 373 | 370 |
| Withdrew: Withdrawal due to infusion related reaction (irr) | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 5 | 7 |
| Withdrew: Substudy stopped by sponsor | 0 | 355 | 352 |
| Withdrew: Reason not specified | 0 | 13 | 8 |
The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits for a minimum of 24 weeks/48 weeks.
| weeks | Ocrelizumab |
|---|---|
| CPD Sustained for at Least 24 weeks | NA (NA to NA) |
| CDP Sustained for at Least 48 weeks | NA (NA to NA) |
CDI is defined as an improvement of ≥1 point on the EDSS score confirmed at a regular scheduled visit at least 24/48 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).
| Percentage of Participants | Ocrelizumab |
|---|---|
| CDI Sustained for 24 weeks: At Week 24 | 95.11 (92.03 to 97.03) |
| CDI Sustained for 24 weeks: At Week 48 | 83.50 (78.81 to 87.24) |
| CDI Sustained for 48 weeks: At Week 48 | 87.54 (83.28 to 90.77) |
The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.
| Percentage of Participants | Ocrelizumab |
|---|---|
| CDP Sustained for 24 weeks: At Week 24 | 99.55 (98.62 to 99.86) |
| CDP Sustained for 24 weeks: At Week 48 | 97.30 (95.75 to 98.29) |
| CDP Sustained for 48 weeks: At Week 48 | 98.05 (96.67 to 98.87) |
CDI is defined as an improvement of 1 point on the EDSS score confirmed at a regular scheduled visit at least 24/48 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).
| Percentage of Participants | Ocrelizumab |
|---|---|
| CDI Sustained for 24 weeks: At Week 48 | 100.0 (100.00 to 100.00) |
| CDI Sustained for 48 weeks: At Week 48 | 100.00 (100.00 to 100.00) |
| CDI Sustained for 24 weeks: At Week 72: | 97.20 (94.22 to 98.66) |
| CDI Sustained for 48 weeks: At Week 72 | 97.60 (94.74 to 98.91) |
| CDI Sustained for 24 weeks: At Week 96 | 90.29 (85.71 to 93.46) |
| CDI Sustained for 48 weeks: At Week 96 | 92.55 (88.41 to 92.55) |
The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.
| Percentage of Particiopants | Ocrelizumab |
|---|---|
| CDP Sustained for 24 weeks: At Week 72 | 93.97 (91.87 to 95.54) |
| CDP Sustained for 48 weeks: At Week 72 | 95.18 (93.25 to 96.56) |
| CDP Sustained for 24 weeks: Week 96 | 91.65 (89.26 to 93.52) |
| CDP Sustained for 48 weeks: Week 96 | 93.47 (91.30 to 95.12) |
CDI is defined as an improvement of 1 point on the EDSS score confirmed at a regular scheduled visit at least 24 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).
| Percentage of Participants | Ocrelizumab |
|---|---|
| CDI Sustained for 24 weeks: At Week 144 | 100.00 (100.00 to 100.00) |
| CDI Sustained for 48 weeks: At Week 144 | 100.00 (100.00 to 100.00) |
| CDI Sustained for 24 weeks: At Week 168 | 99.54 (96.77 to 99.93) |
| CDI Sustained for 48 weeks: At Week 168 | 100.00 (100.00 to 100.00) |
| CDI Sustained for 24 weeks: At Week 192 | 93.77 (89.51 to 96.34) |
| CDI Sustained for 48 weeks: At Week 192 | 98.01 (94.77 to 99.25) |
The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.
| Percentage of Participants | Ocrelizumab |
|---|---|
| CDP Sustained for 24 weeks: At Week 168 | 85.98 (83.04 to 88.44) |
| CDP Sustained for 48 weeks: At Week 168 | 87.98 (85.20 to 90.27) |
| CDP Sustained for 24 weeks: At Week 192 | 84.18 (81.08 to 86.81) |
| CDP Sustained for 48 weeks: At Week 192 | 86.48 (83.54 to 88.93) |
| Percentage of Participants | Ocrelizumab |
|---|---|
| Week 48 Worsened (>0.5) | 9.3 |
| Week 48 Stable (Change <= 0.5 and >= -0.5) | 73.3 |
| Week 48 Improved (<-0.5) | 17.5 |
| Percentage of Participants | Ocrelizumab |
|---|---|
| Week 96 Worsened (>0.5) | 11.9 |
| Week 96 Stable (Change <= 0.5 and >= -0.5) | 76.6 |
| Week 96 Improved (<-0.5) | 11.6 |
| Percentage of Participants | Ocrelizumab |
|---|---|
| Worsened (>0.5) | 9.3 |
| Stable (Change <= 0.5 and >= -0.5) | 81.5 |
| Improved (<-0.5) | 9.2 |
| Percentage of Participants | Ocrelizumab |
|---|---|
| Worsened (>0.5) | 18.0 |
| Stable (Change <= 0.5 and >= -0.5) | 59.3 |
| Improved (<-0.5) | 22.8 |
| Change in Total EDSS Score | Ocrelizumab |
|---|---|
| Mean Change From Baseline in EDSS Score at Week 24 | -0.14 ± 0.68 |
| Change in Total EDSS Score | Ocrelizumab |
|---|---|
| Mean Change From Baseline in EDSS Score at Week 48 | -0.14 ± 0.77 |
| Change in Total EDSS Score | Ocrelizumab |
|---|---|
| Mean Change From Baseline in EDSS Score at Week 72 | -0.09 ± 0.89 |
| Change in Total EDSS Score | Ocrelizumab |
|---|---|
| Mean Change From Baseline in EDSS Score at Week 96 | -0.12 ± 0.95 |
| Change in Total EDSS Score | Ocrelizumab |
|---|---|
| Mean Change From Baseline in EDSS Score at Week 120 | -0.10 ± 0.94 |
| Change in Total EDSS Score | Ocrelizumab |
|---|---|
| Mean Change From Baseline in EDSS Score at Week 144 | -0.10 ± 1.00 |
| Change in Total EDSS Score | Ocrelizumab |
|---|---|
| Mean Change From Baseline in EDSS Score at Week 168 | -0.05 ± 1.05 |
| Change in Total EDSS Score | Ocrelizumab |
|---|---|
| Mean Change From Baseline in EDSS Score at Week 192 | -0.06 ± 1.06 |
Protocol-defined event of disease activity is defined as having at least one of the following: (1). protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis \[MS\], as determined using EDSS/Functional Systems Score \[FSS\] assessment). (2). CDP, as determined using EDSS. (3). a T1 Gd-enhanced lesion after Week 8 (4). a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI) after Week 8 compared to the Week 8 MRI scan.
| Percentage of participants | Ocrelizumab |
|---|---|
| Week 24 | 95.98 (94.20 to 97.23) |
| Week 48 | 88.94 (86.30 to 91.09) |
| Week 72 | 83.94 (80.92 to 86.52) |
| Week 96 | 80.38 (77.14 to 83.21) |
| Week 120 | 77.38 (73.99 to 80.39) |
| Week 144 | 75.76 (72.28 to 78.86) |
| Week 168 | 72.79 (69.18 to 76.05) |
| Week 192 | 70.67 (66.97 to 74.04) |
Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.
| Percentage of Participants | Ocrelizumab |
|---|---|
| Week 24 | 98.52 (97.26 to 99.20) |
| Week 48 | 97.91 (96.50 to 98.76) |
| Week 72 | 96.25 (94.49 to 97.45) |
| Week 96 | 95.32 (93.41 to 96.69) |
| Week 120 | 93.90 (91.78 to 95.49) |
| Week 144 | 93.09 (90.85 to 94.79) |
| Week 168 | 92.43 (90.10 to 94.23) |
| Week 192 | 91.56 (89.12 to 93.48) |
Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment. The adjusted annualized relapse rate is reported which is: Adjusted by age at disease diagnosis, Baseline EDSS, Presence of T1 Gd-enhanced lesion at screening and Presence of relapses in the last year prior to enrollment. Log-transformed exposure time is included as an offset variable. The report contains data up to week 192 of the treatment period of each individual participant.
| events per participant per year | Ocrelizumab |
|---|---|
| Annualized Relapse Rate | 0.02 (0.015 to 0.027) |
| Participants | Substudy - Conventional Infusion | Substudy - Shorter Infusion |
|---|---|---|
| Sub Study: Number of Participants With IRRs Occurring During or Within 24 Hours Following the First Infusion After Randomization to the Shorter Infusion Substudy | 101 | 107 |
Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.
| Percentage of Participants | Ocrelizumab |
|---|---|
| Percentage of Participants Who Are Relapse Free | 92.00 (89.7 to 94.0) |
Protocol-defined disease activity is defined as having at least one of the following: (1). protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis \[MS\], as determined using EDSS/Functional Systems Score \[FSS\] assessment). (2). CDP, as determined using EDSS. (3). a T1 Gd-enhanced lesion after Week 8. (4). a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI) after Week 8 compared to the Week 8 MRI scan. Event-free rate
| Percentage of Participants | Ocrelizumab |
|---|---|
| Week 96 | 80.38 (77.14 to 83.21) |
| Week 144 | 75.76 (72.28 to 78.86) |
| Week 192 | 70.67 (66.97 to 74.04) |
NEP is defined as no progression sustained for at least 24 weeks on all of the following three components (CDP; 20 percent \[%\] increase from baseline in timed 25 Foot Walk Test \[T25FWT\]; 20% increase from baseline in timed 9 hole peg test \[9HPT\]). CDP will be assessed using EDSS.
| Percentage of Participants | Ocrelizumab |
|---|---|
| Week 96 | 79.60 (76.33 to 82.48) |
| Week 192 | 69.16 (65.40 to 72.60) |
NEPAD is defined as no progression on all of the three components of NEP (CDP, T25FWT, 9HPT), no new relapse and no enlarging or new T2 or T1 Gd-enhancing lesion. CDP will be assessed using EDSS. Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.
| Percentage of Participants | Ocrelizumab |
|---|---|
| Week 96 | 70.29 (66.65 to 73.62) |
| Week 192 | 58.89 (54.96 to 62.60) |
MSFC combines the following: Timed 25 Foot Walk Test \[T25FWT\] for leg function \&ambulation measured in seconds (sec). The longer it takes to walk, higher the score indicating deterioration; 9 Hole Peg Test \[9HPT\] for arm \& handf unction measured in sec. Higher score=more time taken to complete test indicating deterioration. Paced Auditory Serial Addition Test \[PASAT\] for cognitive function (score range: 0-60, higher score=better cognitive processing speed). MSFC composite={\[Average(1/9-HPT)-Baseline Mean(1/9-HPT)/Baseline Std Dev(1/9-HPT)\]+\[-(Average T25FWT-Baseline Mean T25FWT)/Baseline Std-Dev T25FWT\]+\[(PASAT-3-BaselineMean PASAT-3)/Baseline Std Dev PASAT-3\]}/ 3.0. MSFC is based on the concept that scores for these 3 dimensions are combined to create a single score to detect change over time in a group of MS patients. Higher composite score=better overall function. Lower score=worse overall function. Higher mean change in total MSFC score=functional improvement at cohort level.
| score on a scale | Ocrelizumab |
|---|---|
| Change at Week 24 | 0.09 ± 0.67 |
| Change at Week 48 | 0.11 ± 0.54 |
| Change at Week 72 | 0.12 ± 0.45 |
| Change at Week 96 | 0.14 ± 0.53 |
| Change at Week 120 | 0.16 ± 0.61 |
| Change at Week 144 | 0.16 ± 0.48 |
| Change at Week 168 | 0.18 ± 0.56 |
| Change at Week 192 | 0.19 ± 0.72 |
The change in the mean score of T25FW is reported below. The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, the higher score, which indicates deterioration. Lower times indicate better performance and greater mobility. Higher times indicate worse performance and greater impairment. Subsequently, the lower the mean change in the score over time, the better performance.
| seconds | Ocrelizumab |
|---|---|
| Change at Week 24 | -0.31 ± 6.62 |
| Change at Week 48 | -0.49 ± 6.88 |
| Change at Week 72 | -0.56 ± 6.99 |
| Change at Week 96 | -0.62 ± 6.95 |
| Change at Week 120 | -0.44 ± 7.94 |
| Change at Week 144 | -0.97 ± 6.25 |
| Change at Week 168 | -0.83 ± 6.64 |
| Change at Week 192 | 0.09 ± 9.37 |
The mean change in 9 Hole Peg Test (9HPT)-score is reported. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. The number of seconds it takes to complete the test, the higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.
| seconds | Ocrelizumab |
|---|---|
| Change at Week 24 | -0.47 ± 14.44 |
| Change at Week 48 | -1.22 ± 11.54 |
| Change at Week 72 | -1.78 ± 8.09 |
| Change at Week 96 | -1.67 ± 10.91 |
| Change at Week 120 | -0.87 ± 15.21 |
| Change at Week 144 | -1.91 ± 8.70 |
| Change at Week 168 | -1.84 ± 10.68 |
| Change at Week 192 | -0.73 ± 17.55 |
Mean change in the Paced Auditory Serial Addition Test \[PASAT\] score is reported. PASAT measures cognitive function. A total of 60 single digit numbers are presented by an audiotape/CD-rom at a constant rate in every 3 seconds (PASAT-3). Participants are required to add each new number to the one immediately before it. Due to the relative complexity of this test, a practice trial with a set of 10 numbers should be performed before the original test. Participants are allowed up to 3 practice trials. Two sets of numbers (forms A \& B) are developed to be used alternatively in every visit to minimize memorizing. The number of correct answers is recorded. The PASAT score ranges from 0 to 60, with higher values representing a better outcome in cognitive processing speed. Subsequently, higher values in mean changes from baseline over the study time indicate improvement in cognitive function.
| score on a scale | Ocrelizumab |
|---|---|
| Change at Week 24 | 4.18 ± 9.26 |
| Change at Week 48 | 5.40 ± 9.52 |
| Change at Week 72 | 6.33 ± 11.59 |
| Change at Week 96 | 7.66 ± 10.93 |
| Change at Week 120 | 7.69 ± 12.95 |
| Change at Week 144 | 8.45 ± 10.02 |
| Change at Week 168 | 8.47 ± 11.79 |
| Change at Week 192 | 9.64 ± 11.56 |
BICAMS is assessing cognitive processing speed and verbal and visual memory. SDMT assesses processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 second time span. The higher the results, the better processing speed/working memory.
| responses over 90 seconds | Ocrelizumab |
|---|---|
| Change at Week 48 | 2.48 ± 10.12 |
| Change at Week 96 | 1.89 ± 9.98 |
| Change at Week 144 | 3.33 ± 9.31 |
| Change at Week 192 | 4.38 ± 10.38 |
BICAMS assesses cognitive processing speed and verbal and visual memory. The CLVT-II is an assessment of verbal learning and memory which measures recall and recognition scores, encoding strategies, learning rates and error types. A list learning task with 16 words from 4 semantic categories are read over a series of 5 list presentations. Recall is assessed after learning and at a 20-minute delay. The maximum possible score is 80 and a minimum is 0. A higher score indicated better recall.
| score on a scale | Ocrelizumab |
|---|---|
| Change at Week 48 | 2.02 ± 8.29 |
| Change at Week 96 | 2.71 ± 9.25 |
| Change at Week 144 | 3.99 ± 7.60 |
| Change at Week 192 | 4.28 ± 13.76 |
BICAMS assesses cognitive processing speed and verbal and visual memory. BVMT-R assesses visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.
| points on a scale | Ocrelizumab |
|---|---|
| Baseline | 23.69 ± 6.44 |
| Change at Week 48 | -0.71 ± 5.31 |
| Change at Week 96 | 0.82 ± 5.68 |
| Change at Week 144 | 3.15 ± 5.37 |
| Change at Week 192 | 1.06 ± 7.09 |
Number of Lesions are categorized as followed: 1, 2, 3, \>1, \>3
| Number of Lesions | Ocrelizumab |
|---|---|
| Week 24 Number of Lesions 0 | 659 |
| Week 24 Number of Lesions 1 | 6 |
| Week 24 Number of Lesions 2 | 2 |
| Week 24 Number of Lesions >1 | 2 |
| Week 48 Number of Lesions 0 | 650 |
| Week 48 Number of Lesions 1 | 7 |
| Week 96 Number of Lesions 0 | 629 |
| Week 96 Number of Lesions 1 | 1 |
| Week 144 Number of Lesions 0 | 567 |
| Week 144 Number of Lesions 1 | 1 |
| Week 144 Number of Lesions 3 | 1 |
| Week 144 Number of Lesions >1 | 1 |
| Week 192 Number of Lesions 0 | 545 |
| Week 192 Number of Lesions 1 | 1 |
Number of Lesions are categorized as followed: 1, 2, 3, \>1
| Number of Lesions | Ocrelizumab |
|---|---|
| Week 24 Number of Lesions 0 | 651 |
| Week 24 Number of Lesions 1 | 13 |
| Week 24 Number of Lesions 2 | 3 |
| Week 24 Number of Lesions >1 | 3 |
| Week 48 Number of Lesions 0 | 644 |
| Week 48 Number of Lesions 1 | 11 |
| Week 48 Number of Lesions 2 | 3 |
| Week 48 Number of Lesions 3 | 2 |
| Week 48 Number of Lesions >1 | 5 |
| Week 96 Number of Lesions 0 | 624 |
| Week 96 Number of Lesions 1 | 8 |
| Week 96 Number of Lesions 2 | 1 |
| Week 96 Number of Lesions >1 | 1 |
| Week 144 Number of Lesions 0 | 564 |
| Week 144 Number of Lesions 1 | 6 |
| Week 144 Number of Lesions 2 | 1 |
| Week 144 Number of Lesions 3 | 1 |
| Week 144 Number of Lesions >1 | 2 |
| Week 192 Number of Lesions 0 | 546 |
| Week 192 Number of Lesions 1 | 4 |
| Week 192 Number of Lesions 2 | 1 |
| Week 192 Number of Lesions >1 | 1 |
| Micro Liter | Ocrelizumab |
|---|---|
| Week 48 | -310.63 ± 708.07 |
| Week 96 | -405.61 ± 755.99 |
| Week 144 | -359.76 ± 761.84 |
| Week 192 | -307.64 ± 797.87 |
Fluid-Attenuated Inversion-Recovery (FLAIR) Lesion as Detected by Brain MRI was measured for its volumes.
| Number of Lesions | Ocrelizumab |
|---|---|
| Baseline Week 8 0 | 633 |
| Baseline Week 8 1 | 6 |
| Week 24 0 | 635 |
| Week 24 1 | 6 |
| Week 48 0 | 631 |
| Week 48 1 | 6 |
| Week 96 0 | 611 |
| Week 96 1 | 7 |
| Week 144 0 | 550 |
| Week 144 1 | 5 |
| Week 192 0 | 530 |
| Week 192 1 | 5 |
Percentage change from Normalized brain volume in cm3 (cubic centimeter)values are reported
| Percentage Change in Volume (cm3) | Ocrelizumab |
|---|---|
| Week 24 | -0.189 ± 0.564 |
| Week 48 | -0.479 ± 0.733 |
| Week 96 | -0.909 ± 0.930 |
| Week 144 | -1.283 ± 1.156 |
| Week 192 | -1.535 ± 1.311 |
| Percentage % | Ocrelizumab |
|---|---|
| Week 24 | 98.97 (97.85 to 99.51) |
| Week 48 | 97.49 (96.00 to 98.45) |
| Week 72 | 96.02 (94.25 to 97.25) |
| Week 96 | 93.51 (91.38 to 95.13) |
| Week 120 | 92.04 (89.73 to 93.84) |
| Week 144 | 89.23 (86.65 to 91.34) |
| Week 168 | 87.17 (84.41 to 89.47) |
| Week 192 | 83.85 (80.85 to 86.42) |
WPAI scale measures impact of health problems on work productivity and regular activities: Absenteeism (Work Time Missed) measuring % of work time missed due to health issues; Presenteeism:Calculated as the percentage of impairment while working due to health problems. Overall Work Impairment:Calculated by combining absenteeism and presenteeism using the formula:Overall Work Impairment=Absenteeism+(1-Absenteeism)×Presenteeism Overall Work Impairment=Absenteeism+(1-Absenteeism)×Presenteeism This formula accounts for both the time missed and the reduced productivity while at work. Activity Impairment: Calculated as the percentage of impairment in regular activities outside of work. Range: Each component is scored as 0%-100%). Higher % indicate greater impairment and worse outcomes.
| WAPI Sub-Score | Ocrelizumab |
|---|---|
| Work productivity Baseline | 26.33 ± 31.84 |
| Work productivity Week 24 | 17.65 ± 25.04 |
| Work productivity Week 48 | 18.83 ± 25.92 |
| Work productivity Week 96 | 16.46 ± 23.10 |
| Work productivity Week 144 | 16.78 ± 23.85 |
| Work productivity Week 192 | 15.80 ± 22.25 |
| Activity Impairment Baseline | 23.23 ± 24.79 |
| Activity Impairment Week 24 | 18.09 ± 22.15 |
| Presenteeism Week 48 | 18.85 ± 23.37 |
| Activity Impairment Week 96 | 17.79 ± 22.92 |
| Activity Impairment Week 144 | 17.80 ± 23.74 |
| Activity Impairment Week 192 | 18.18 ± 23.25 |
The SMSS consists of 12 items which are assessed on a seven-point Likert scale that ranges from 0 (not at all affected) to 6 (total limitation) \[7\]. The total score ranges from 0 to 72, with higher scores indicating more severe symptom endorsement.
| Change in SymptoMScreen Composite Score | Ocrelizumab |
|---|---|
| Week 24 | -0.1 ± 0.9 |
| Week 48 | -0.1 ± 1.0 |
| Week 96 | 0.0 ± 1.1 |
| Week 144 | 0.0 ± 1.1 |
| Week 192 | 0.0 ± 1.1 |
The 29-item Multiple Sclerosis Impact Scale (MSIS-29) is a questionnaire to examine the impact of multiple sclerosis (MS) on physical and psychological functioning from a patient's perspective, which includes 29 items self-reported measures associated with a physical scale and 9 items with a psychological scale. MSIS-29 scales are generated by summing items and it's ranging from 29-145'. The higher total MSIS-29 scores indicate a greater degree of disability. The mean change in MSIS-29 scores from baseline is reported. The decreasing values in the mean change from baseline indicate functional improvement from patients' perspective
| Change in MSIS-29 Mean Score | Ocrelizumab |
|---|---|
| Week 24 | -2.43 ± 12.13 |
| Week 48 | -2.15 ± 13.04 |
| Week 96 | -1.26 ± 14.31 |
| Week 144 | -0.73 ± 14.83 |
| Week 192 | -0.63 ± 16.04 |
| Percentage of Participants | Ocrelizumab |
|---|---|
| Adverse Events | 95.8 |
| Serious Adverse Events | 15.0 |
| Participants | Substudy - Conventional Infusion | Substudy - Shorter Infusion |
|---|---|---|
| All Randomized Doses (Overall) | 155 | 172 |
| 1st Randomized Dose | 101 | 107 |
| 2nd Randomized Dose | 84 | 96 |
| 3rd Randomized Dose | 62 | 82 |
| 4th Randomized Dose | 14 | 17 |
| 5th Randomized Dose | 1 | 3 |
| 6th Randomized Dose | 0 | 0 |
The number of participants with IRRs by most extreme intensity were reported (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 =life-threatening, grade 5 = fatal). Multiple IRRs in one participant are counted only once at the most extreme (highest) intensity observed.
| Participants | Substudy - Conventional Infusion | Substudy - Shorter Infusion |
|---|---|---|
| Grade 1 (Mild) | 88 | 92 |
| Grade 2 (Moderate) | 66 | 76 |
| Grade 3 (Severe) | 1 | 4 |
| Grade 4 (Life-Threatening) | 0 | 0 |
| Grade 5 (Fatal) | 0 | 0 |
| symptoms | Substudy - Conventional Infusion | Substudy - Shorter Infusion |
|---|---|---|
| Substudy: Number of IRR Symptoms | 471 | 458 |
| symptoms | Substudy - Conventional Infusion | Substudy - Shorter Infusion |
|---|---|---|
| Substudy: IRRs Leading to Treatment Discontinuation | 0 | 0 |
Collected over Main study: Up to 4 Years Sub-study: Week 24 to Week 144. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ocrelizumab | 13/1,225 (1.1%) | 184/1,225 (15%) | 1,110/1,225 (90.6%) |
| Substudy - Conventional Infusion | 2/370 (0.5%) | 21/370 (5.7%) | 251/370 (67.8%) |
| Substudy - Shorter Infusion | 1/375 (0.3%) | 19/375 (5.1%) | 276/375 (73.6%) |
| Event | Ocrelizumab | Substudy - Conventional Infusion | Substudy - Shorter Infusion |
|---|---|---|---|
| COVID-19Infections and infestations | 23/1225 | 2/370 | 1/375 |
| COVID-19 PNEUMONIAInfections and infestations | 17/1225 | 0/370 | 2/375 |
| MULTIPLE SCLEROSIS RELAPSENervous system disorders | 9/1225 | 0/370 | 0/375 |
| PNEUMONIAInfections and infestations | 8/1225 | 0/370 | 1/375 |
| ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions | 7/1225 | 1/370 | 0/375 |
| URINARY TRACT INFECTIONInfections and infestations | 5/1225 | 0/370 | 2/375 |
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 6/1225 | 0/370 | 1/375 |
| APPENDICITISInfections and infestations | 5/1225 | 0/370 | 1/375 |
| PYELONEPHRITISInfections and infestations | 4/1225 | 0/370 | 0/375 |
| ABORTION INDUCEDSurgical and medical procedures | 4/1225 | 0/370 | 0/375 |
| Event | Ocrelizumab | Substudy - Conventional Infusion | Substudy - Shorter Infusion |
|---|---|---|---|
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 674/1225 | 154/370 | 172/375 |
| NASOPHARYNGITISInfections and infestations | 320/1225 | 58/370 | 50/375 |
| HEADACHENervous system disorders | 295/1225 | 46/370 | 37/375 |
| COVID-19Infections and infestations | 291/1225 | 14/370 | 13/375 |
| FATIGUEGeneral disorders | 201/1225 | 28/370 | 28/375 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 196/1225 | 28/370 | 35/375 |
| URINARY TRACT INFECTIONInfections and infestations | 184/1225 | 20/370 | 24/375 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 133/1225 | 18/370 | 14/375 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 132/1225 | 17/370 | 15/375 |
| COUGHRespiratory, thoracic and mediastinal disorders | 126/1225 | 13/370 | 18/375 |
| Age, Continuous(Years) | Ocrelizumab |
|---|---|
| Mean | 32.7 ± 9.1 |
| Sex: Female, Male(Participants) | Ocrelizumab |
|---|---|
| Female | 784 |
| Male | 441 |
| Ethnicity (NIH/OMB)(Participants) | Ocrelizumab |
|---|---|
| Hispanic or Latino | 145 |
| Not Hispanic or Latino | 960 |
| Unknown or Not Reported | 120 |
| Race (NIH/OMB)(Participants) | Ocrelizumab |
|---|---|
| American Indian or Alaska Native | 11 |
| Asian | 19 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 34 |
| White | 1007 |
| More than one race | 37 |
| Unknown or Not Reported | 115 |
Showing the first 100 of 193 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Mar 2017 to primary completion in Apr 2023, 73 months.
Results were first posted in Jan 2025, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab
Multiple Sclerosis, Relapsing-Remitting →